Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor (HER2), leading to high failure rates in traditional treatments [52]. This evidence concerns the gene PGR and triple-negative breast carcinoma.